# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Suraj Kalia downgrades Edwards Lifesciences (NYSE:EW) from Outperform to Perform.
Evercore ISI Group analyst Vijay Kumar upgrades Edwards Lifesciences (NYSE:EW) from In-Line to Outperform and raises the pri...
Edwards Lifesciences (NYSE: EW) has outperformed the market over the past 20 years by 7.57% on an annualized basis producing an...
Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $95 to $85.
Millennium Management's Q2 2025 13F reveals big bets on crypto (IBIT, PLTR) & healthcare (EW, INSM), with tech rebalanc...